Inflammation and erythropoietin hyporesponsiveness

Role of pentoxifylline, an anti TNF-α agent

Nitya Nand, Virender Chauhan, Shashi Seth, Nisha Batra, Savio Dsouza

Research output: Contribution to journalArticle

Abstract

Introduction: Resistance to erythropoiesis-stimulating agents (ESAs) is often associated with chronic inflammation present in patients of chronic kidney disease (CKD) on maintenance haemodialysis (MHD). This study was planned to investigate how anaemia, ESA resistance and the plasma levels of biological markers of inflammation are interlinked to each other, and whether pentoxifylline (PTF) has any role in improving anaemia in these subset of patients. Methods: 20 adult patients of end-stage renal disease (ESRD) with erythropoietin hyporesponsiveness undergoing twice weekly maintenance haemodialysis were administered subcutaneously 6,000 IU of recombinant human erythropoietin (rHuEPo) twice weekly following dialysis for two months followed by addition of pentoxifylline to erythropoietin for next four months to complete the study period of six months. The effect of erythropoietin and pentoxifylline on haemoglobin, haematocrit, and inflammatory markers that included high-sensitivity C-reactive protein (hsCRP), tumour necrosis factor alpha (TNF-α), erythrocyte sedimentation rate (ESR), serum albumin, and serum ferritin were studied. Results: There was a insignificant response of erythropoietin alone on haemoglobin and haematocrit after 2 months of rHuePo therapy (‘p’ > 0.05), associated with insignificant decrease in hsCRP, TNF-α and ESR, respectively over 2 months but when pentoxifylline was added to erythropoietin, the rise in haemoglobin and haematocrit was highly significant (‘p’ < 0.01) which was associated with highly significant decrease in hsCRP, TNF-α and ESR, respectively after completion of the study (‘p’ < 0.01). Conclusion: Pentoxifylline has significant effect in reducing the inflammatory parameters in CKD patients on MHD and therefore is a promising agent in improving anaemia in patients of ESRD showing erythropoietin hyporesponsiveness, attributable to inflammation.

Original languageEnglish
Pages (from-to)16-20
Number of pages5
JournalJournal, Indian Academy of Clinical Medicine
Volume17
Issue number1
Publication statusPublished - 01-01-2016

Fingerprint

Pentoxifylline
Erythropoietin
Tumor Necrosis Factor-alpha
Inflammation
Blood Sedimentation
Hematocrit
C-Reactive Protein
Hematinics
Renal Dialysis
Anemia
Hemoglobins
Maintenance
Chronic Renal Insufficiency
Chronic Kidney Failure
Ferritins
Serum Albumin
Dialysis
Biomarkers
Serum

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Nand, Nitya ; Chauhan, Virender ; Seth, Shashi ; Batra, Nisha ; Dsouza, Savio. / Inflammation and erythropoietin hyporesponsiveness : Role of pentoxifylline, an anti TNF-α agent. In: Journal, Indian Academy of Clinical Medicine. 2016 ; Vol. 17, No. 1. pp. 16-20.
@article{d8de919d91864af8bda6268e0fda0a80,
title = "Inflammation and erythropoietin hyporesponsiveness: Role of pentoxifylline, an anti TNF-α agent",
abstract = "Introduction: Resistance to erythropoiesis-stimulating agents (ESAs) is often associated with chronic inflammation present in patients of chronic kidney disease (CKD) on maintenance haemodialysis (MHD). This study was planned to investigate how anaemia, ESA resistance and the plasma levels of biological markers of inflammation are interlinked to each other, and whether pentoxifylline (PTF) has any role in improving anaemia in these subset of patients. Methods: 20 adult patients of end-stage renal disease (ESRD) with erythropoietin hyporesponsiveness undergoing twice weekly maintenance haemodialysis were administered subcutaneously 6,000 IU of recombinant human erythropoietin (rHuEPo) twice weekly following dialysis for two months followed by addition of pentoxifylline to erythropoietin for next four months to complete the study period of six months. The effect of erythropoietin and pentoxifylline on haemoglobin, haematocrit, and inflammatory markers that included high-sensitivity C-reactive protein (hsCRP), tumour necrosis factor alpha (TNF-α), erythrocyte sedimentation rate (ESR), serum albumin, and serum ferritin were studied. Results: There was a insignificant response of erythropoietin alone on haemoglobin and haematocrit after 2 months of rHuePo therapy (‘p’ > 0.05), associated with insignificant decrease in hsCRP, TNF-α and ESR, respectively over 2 months but when pentoxifylline was added to erythropoietin, the rise in haemoglobin and haematocrit was highly significant (‘p’ < 0.01) which was associated with highly significant decrease in hsCRP, TNF-α and ESR, respectively after completion of the study (‘p’ < 0.01). Conclusion: Pentoxifylline has significant effect in reducing the inflammatory parameters in CKD patients on MHD and therefore is a promising agent in improving anaemia in patients of ESRD showing erythropoietin hyporesponsiveness, attributable to inflammation.",
author = "Nitya Nand and Virender Chauhan and Shashi Seth and Nisha Batra and Savio Dsouza",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "17",
pages = "16--20",
journal = "Journal, Indian Academy of Clinical Medicine",
issn = "0972-3560",
publisher = "Indian Academy of Clinical Medicine",
number = "1",

}

Inflammation and erythropoietin hyporesponsiveness : Role of pentoxifylline, an anti TNF-α agent. / Nand, Nitya; Chauhan, Virender; Seth, Shashi; Batra, Nisha; Dsouza, Savio.

In: Journal, Indian Academy of Clinical Medicine, Vol. 17, No. 1, 01.01.2016, p. 16-20.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inflammation and erythropoietin hyporesponsiveness

T2 - Role of pentoxifylline, an anti TNF-α agent

AU - Nand, Nitya

AU - Chauhan, Virender

AU - Seth, Shashi

AU - Batra, Nisha

AU - Dsouza, Savio

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Introduction: Resistance to erythropoiesis-stimulating agents (ESAs) is often associated with chronic inflammation present in patients of chronic kidney disease (CKD) on maintenance haemodialysis (MHD). This study was planned to investigate how anaemia, ESA resistance and the plasma levels of biological markers of inflammation are interlinked to each other, and whether pentoxifylline (PTF) has any role in improving anaemia in these subset of patients. Methods: 20 adult patients of end-stage renal disease (ESRD) with erythropoietin hyporesponsiveness undergoing twice weekly maintenance haemodialysis were administered subcutaneously 6,000 IU of recombinant human erythropoietin (rHuEPo) twice weekly following dialysis for two months followed by addition of pentoxifylline to erythropoietin for next four months to complete the study period of six months. The effect of erythropoietin and pentoxifylline on haemoglobin, haematocrit, and inflammatory markers that included high-sensitivity C-reactive protein (hsCRP), tumour necrosis factor alpha (TNF-α), erythrocyte sedimentation rate (ESR), serum albumin, and serum ferritin were studied. Results: There was a insignificant response of erythropoietin alone on haemoglobin and haematocrit after 2 months of rHuePo therapy (‘p’ > 0.05), associated with insignificant decrease in hsCRP, TNF-α and ESR, respectively over 2 months but when pentoxifylline was added to erythropoietin, the rise in haemoglobin and haematocrit was highly significant (‘p’ < 0.01) which was associated with highly significant decrease in hsCRP, TNF-α and ESR, respectively after completion of the study (‘p’ < 0.01). Conclusion: Pentoxifylline has significant effect in reducing the inflammatory parameters in CKD patients on MHD and therefore is a promising agent in improving anaemia in patients of ESRD showing erythropoietin hyporesponsiveness, attributable to inflammation.

AB - Introduction: Resistance to erythropoiesis-stimulating agents (ESAs) is often associated with chronic inflammation present in patients of chronic kidney disease (CKD) on maintenance haemodialysis (MHD). This study was planned to investigate how anaemia, ESA resistance and the plasma levels of biological markers of inflammation are interlinked to each other, and whether pentoxifylline (PTF) has any role in improving anaemia in these subset of patients. Methods: 20 adult patients of end-stage renal disease (ESRD) with erythropoietin hyporesponsiveness undergoing twice weekly maintenance haemodialysis were administered subcutaneously 6,000 IU of recombinant human erythropoietin (rHuEPo) twice weekly following dialysis for two months followed by addition of pentoxifylline to erythropoietin for next four months to complete the study period of six months. The effect of erythropoietin and pentoxifylline on haemoglobin, haematocrit, and inflammatory markers that included high-sensitivity C-reactive protein (hsCRP), tumour necrosis factor alpha (TNF-α), erythrocyte sedimentation rate (ESR), serum albumin, and serum ferritin were studied. Results: There was a insignificant response of erythropoietin alone on haemoglobin and haematocrit after 2 months of rHuePo therapy (‘p’ > 0.05), associated with insignificant decrease in hsCRP, TNF-α and ESR, respectively over 2 months but when pentoxifylline was added to erythropoietin, the rise in haemoglobin and haematocrit was highly significant (‘p’ < 0.01) which was associated with highly significant decrease in hsCRP, TNF-α and ESR, respectively after completion of the study (‘p’ < 0.01). Conclusion: Pentoxifylline has significant effect in reducing the inflammatory parameters in CKD patients on MHD and therefore is a promising agent in improving anaemia in patients of ESRD showing erythropoietin hyporesponsiveness, attributable to inflammation.

UR - http://www.scopus.com/inward/record.url?scp=84969944934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969944934&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 16

EP - 20

JO - Journal, Indian Academy of Clinical Medicine

JF - Journal, Indian Academy of Clinical Medicine

SN - 0972-3560

IS - 1

ER -